P098 Novel drug candidate for the treatment of Inflammatory Bowel Disease with unique mechanisms of action

Abstract Background Inflammatory Bowel Disease (IBD) is characterized by chronic inflammation and severe dysfunction of the gastrointestinal tract. Despite significant improvements in therapeutic agents targeting IBD, many subjects with IBD fail to achieve recovery or do not respond current medication. Moreover, therapy has been limited management inflammation, while almost no progress made development anti-fibrotic therapies for IBD. NEXEL's novel protein NP-011, αVβ3 αVβ5 integrins phosphatidylserine, shown anti-inflammatory effects various vivo models fibrosis. This study was designed evaluate potential NP-011 treatment using mice models. Methods Acute ulcerative colitis induced exposure 2% dextran sodium sulfate (DSS)-treated drinking water from Day 1 7; Normal control animals did receive DSS. Animals were then dosed vehicle (NP-011 storage buffer, n=10), comparative protein, MFG-E8 (n=10), (n=10) daily five days (IV) 7 11. All sacrificed on 14. The model DSS-treated (initial three consecutive each week) recovered providing normal (four 3 10). vehicle, commercial drugs (n=10, 1.03 mg/kg, 3), 320, 640 ug/kg, 10) intravenous injection. 18. Colon length histological changes (inflammation crypt damage) analyzed. Results induction weight loss. Treatment improved body gain during recovery. Both proteins suppressed shortening colon reduced score, including intestinal damage. Notably, administration showed higher efficiency than same dose improving these pathologic parameters. also effective colitis. shortening, reactions, damage markedly attenuated NP-011-administered comparable efficacy drugs. Conclusion demonstrated substantial improvement characteristics bowel pathology suppression model. Taken together, this could be a promising drug candidate unique mechanisms action, anti-inflammation anti-fibrosis *JL, GK, JCK have equally contributed study.